Axitinib is a targeted therapy drug used in the treatment of metastatic renal cell carcinoma (RCC). It works to block certain proteins, known as vascular endothelial growth factor receptors (VEGFRs), from growing and spreading. This allows for improved outcomes in patients with this form of cancer. However, like other treatments, there are risks and side effects associated with its use. In this article, we will discuss what you need to know about axitinib in order to make informed decisions about your treatment plan. We will explore how it works, the different types available, common side effects associated with use, and other important information that can help you feel confident in your choice of treatment.
Axitinib is a targeted cancer therapy that works by inhibiting the activity of tyrosine kinase enzymes. These enzymes are involved in the growth and spread of cancer cells. Axitinib is used to treat renal cell carcinoma (RCC), a type of kidney cancer. It is typically used after other treatments, such as surgery, have failed. Axitinib may also be used to treat other types of cancers, such as thyroid cancer or non-small cell lung cancer (NSCLC).
Axitinib belongs to a class of drugs known as kinase inhibitors. Kinase inhibitors work by blocking the activity of certain enzymes, which can help stop the growth and spread of cancer cells. Axitinib is a targeted therapy, which means it targets specific molecules that are involved in the growth and spread of cancer cells. Axitinib inhibits the activity of tyrosine kinase enzymes. These enzymes are found in healthy cells, but they are overactive in cancer cells. By inhibiting these enzymes, axitinib can help stop the growth and spread of cancer cells.
Axitinib works by inhibiting the vascular endothelial growth factor (VEGF) receptor. This protein is responsible for the growth and development of new blood vessels. When the VEGF receptor is inhibited, blood vessel growth is prevented, which in turn slows down the growth of cancerous tumors. Axitinib has been shown to be effective in treating several types of cancer, including renal cell carcinoma, gastrointestinal stromal tumor, and thyroid cancer.
The most common side effects of Axitinib are diarrhea, fatigue, high blood pressure, loss of appetite, and nausea. Less common side effects include bleeding, brain hemorrhage, heart attack, kidney failure, and liver damage. Some of the more rare side effects include hair loss, skin rash, and vision changes.
If you miss a dose of axitinib, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Axitinib is a powerful cancer-fighting drug that can be used to treat certain types of tumors. While the side effects and risks associated with its use must always be taken into account, it has been proven effective in many cases. With careful monitoring and guidance from your oncologist or hematologist, axitinib can be incorporated into an individualized treatment plan that helps you manage your disease while minimizing any potential adverse reactions.
1.
'Chemo brain' cognitive issues linked to poor lymphatic-system drainage
2.
First-Line HCC Trial's Lenvatinib-Pembrolizumab Combo Misses Target.
3.
Anti-PD-L1 Plus Targeted Agent No Better Than Chemo for Resistant NSCLC
4.
Advanced Solid Tumors May Benefit from Investigative Immunotherapy Combo.
5.
For the treatment of paroxysmal nocturnal hemoglobinuria, the FDA has approved an oral factor B inhibitor.
1.
All You Need To Know About Partial Thromboplastin Time (PTT) Test
2.
Optimizing Cancer Care: Multidisciplinary Approaches and Supportive Strategies
3.
Multimodal Data Fusion with Deep Neural Networks - Revolutionizing Oncology with Precision Cancer Diagnosis 2025
4.
Gene Signatures and Their Implications in Oncology: Decoding the Blueprint for Personalized Cancer Treatment
5.
Breakthroughs in Cancer Care: From Rare Diagnoses to Advanced and Early-Stage Treatments
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
2.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
3.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
4.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation